Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

talazoparib

Trade Name:
bmn-673
Company:
Status:
Completed (Results Pending)
Agent Chaperone(s):
Treatment Protocol:
Talazoparib is a Poly(ADP-ribose) polymerase (PARP) Inhibitor. Talazoparib was orally administered at 1 mg daily with Irinotecan at 25 mg/m2 once every 2 weeks by infusion (q2w) for 12 total weeks.This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
May 22, 2016
Date Left I-SPY:
April 7, 2017
No. Participants in Arm:
74
Graduating Subtypes:
Agent Description:

Talazoparib is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) that selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link